¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"diffuse, mixed small and large cell lymphoma"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
  • cell bank
    ¼¼Æ÷ÀºÇà
  • cell body
    ¼¼Æ÷ü
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • cell culture
    ¼¼Æ÷¹è¾ç
  • cell cycle
    ¼¼Æ÷ÁÖ±â
  • cell death
    ¼¼Æ÷»ç
  • cell dedifferentiation
    ¼¼Æ÷Å»ºÐÈ­
  • cell division
    ¼¼Æ÷ºÐ¿­
  • cell envelope
    ¼¼Æ÷²®Áú, ¼¼Æ÷ÇǸ·
  • cell fusion
    ¼¼Æ÷À¶ÇÕ
  • cell inclusion
    ¼¼Æ÷Æ÷ÇÔ¹°, ¼¼Æ÷ºÀÀÔü
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cell labeling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • cell interaction
    ¼¼Æ÷»óÈ£ÀÛ¿ë
  • cell lethality
    ¼¼Æ÷Ä¡»çÀ²
  • cell line
    ¼¼Æ÷°è, ¼¼Æ÷ÁÖ
  • cell loss
    ¼¼Æ÷¼Ò½Ç
  • cell mass
    ¼¼Æ÷µ¢ÀÌ
  • cell membrane
    ¼¼Æ÷¸·
  • cell organelle
    ¼¼Æ÷¼Ò±â°ü
  • cell respiration
    ¼¼Æ÷È£Èí
  • cell strain
    ¼¼Æ÷ÁÖ
  • cell substitution
    ¼¼Æ÷´ëÄ¡, Ç÷±¸´ëÄ¡
  • cell swelling
    ¼¼Æ÷Á¾Ã¢
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ
  • cell agar plate
    ¼¼Æ÷¿ì¹«ÆòÆÇ
  • cell color ratio
    ÀûÇ÷±¸»ö¼Òºñ
  • cell labeling technique
    ¼¼Æ÷Ç¥Áö±â¹ý
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • anoxic cell
    ¹«»ê¼Ò¼¼Æ÷
  • anti-idiotypic T suppressor cell
    Ç×°³º°Æ¯ÀÌÇü ¾ïÁ¦T¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×üÀÇÁ¸ ¼¼Æ÷¸Å°³ ¼¼Æ÷µ¶¼º.
  • antibody forming cell
    Ç×ü»ý»ê¼¼Æ÷(ù÷ô÷ßæß§á¬øà).
  • antibody producing cell
    Ç×ü»ý»ê¼¼Æ÷
  • antigen presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷.
  • antigen reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷.
  • apex of cell
    ¼¼Æ÷²À´ë±â
  • apical cell
    Á¤(´Ü)¼¼Æ÷(ð¢Ó®á¬øà)
  • argentaffin chromaffin cell
    Å©·Òģȭ¼º ¼¼Æ÷
  • argyrophil(e) cell
    ÀºÄ£È­¼º ¼¼Æ÷(ëÞöÑûúàõá¬øà)
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º(Ý÷áÈàõ) ±âÀú¼¼Æ÷¾Ï
  • arteritis,giant cell of aorta
    ´ëµ¿¸Æ(ÓÞÔÑØæ)ÀÇ °Å¼¼Æ÷¼º(ËÝá¬øààõ)
  • free cell
    ÀÚÀ¯¼¼Æ÷(í»ë¦á¬øà).
  • functional cell
    ±â´É¼¼Æ÷(ѦÒöá¬øà).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • diffuse intravascular coagulation
    ¹ü¹ß¼º Ç÷°ü³»ÀÀ°í.
  • diffuse intravascular coagulopathy
    ¹ü¹ß¼º Ç÷°ü³» ÀÀ°íº´Áõ.
  • diffuse intravascular coagulopathy
    ¹Ì¸¸¼º ¹ü¹ß¼º Ç÷°ü³» ÀÀ°íº´Áõ.
  • diffuse labyrinthitis
    ¹Ì¸¸(¼º) ³»ÀÌ¿°, ¹Ì¸¸(¼º) ¹Ì·Î
  • diffuse nontoxic goiter
    ¹ü¹ß¼º ºñÁßµ¶¼º °©»ó¼±Á¾(¹ü¹ß¼ººñÁßµ¶¼º°©»ó¼±Á¾) .
  • diffuse nontoxic goiter
    ¹ü¹ß¼º ºñÁßµ¶¼º °©»ó¼±Á¾(ÛñÛ¡àõÞªñéÔ¸àõË£ßÒàÍðþ) .
  • diffuse pericementitis
    ¹Ì¸¸¼º Ä¡±Ù¸·¿°(¡­öÍÐÆØ¯æú).
  • diffuse peritonitis
    ¹Ì¸¸¼º º¹¸·¿°(¡­º¹¸·¿°).
  • diffuse peritonitis
    ¹Ì¸¸¼º º¹¸·¿°(¡­ÜÙØ¯æú).
  • diffuse placenta
    ÆÛÁøÅ¹Ý
  • diffuse reflection
    ¹Ì¸¸¼º ¹Ý»ç (گؼàõ ÚãÞÒ)
  • diffuse reflectors
    ¹Ì¸¸¼º ¹Ý»çü (گؼàõ ÚãÞÒô÷)
  • diffuse scleritis
    ±¤¹üÀ§°ø¸·¿°, ¹Ì¸¸¼º°ø¸·¿°
  • diffuse scleroderma
    ±¤¹üÀ§ ÇǺΠ°æÈ­Áõ
  • diffuse sclerosis
    ¹ü¹ß¼º °æÈ­Áõ(ÛñÛ¡àõÌãûùñø).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • Glial cell of central nervous system
    ÁßÃ߾Ʊ³¼¼Æ÷
    [¿¾ ¿ë¾î] ÁßÃß±³¼¼Æ÷
  • Mesothelial cell
    ÁßÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ÁßÇǼ¼Æ÷
  • Cuticular cell
    Áý²®Áú¼¼Æ÷
    [¿¾ ¿ë¾î] ¼ÒÇǼ¼Æ÷
  • Fenestrated endothelial cell
    â³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] À¯Ã¢³»ÇǼ¼Æ÷
  • Interdental cell
    û°¢Ä¡¾Æ»çÀ̼¼Æ÷
    [¿¾ ¿ë¾î] ûġ°£¼¼Æ÷
  • Merkel`s cell
    Ã˰¢¼¼Æ÷
    [¿¾ ¿ë¾î] MerkelÃ˰¢¼¼Æ÷
  • Macula densa cell
    Ä¡¹Ð¹ÝÁ¡¼¼Æ÷
    [¿¾ ¿ë¾î] Ä¡¹Ð¹Ý¼¼Æ÷
  • Chromaffin cell
    ģũ·Ò¼¼Æ÷
    [¿¾ ¿ë¾î] Å©·Òģȭ¼¼Æ÷
  • Golgi cell
    Å«º°¼¼Æ÷
    [¿¾ ¿ë¾î] °ñÁö¼¼Æ÷
  • Decidual cell
    Å»¶ô¸·¼¼Æ÷
    [¿¾ ¿ë¾î] Å»¶ô¸·¼¼Æ÷
  • Cuticular cell
    Åв®Áú¼¼Æ÷
    [¿¾ ¿ë¾î] ¸ð¼ÒÇǼ¼Æ÷
  • Matrix cell
    ÅйÙÅÁÁú¼¼Æ÷
    [¿¾ ¿ë¾î] ¸ð±âÁú¼¼Æ÷
  • Hair cell
    Åм¼Æ÷
    [¿¾ ¿ë¾î] À¯¸ð°¨°¢¼¼Æ÷
  • Juxtaglomerular cell
    Å丮°ç¼¼Æ÷
    [¿¾ ¿ë¾î] »ç±¸Ã¼¹æ¼¼Æ÷
  • Flagellated epithelial cell
    Æí¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Æí¸ð»óÇǼ¼Æ÷
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
SCCL small cell carcinoma of the lung
SCLC small cell lung carcinoma
LML large and medium lymphocytes; left mediolateral; left middle lobe
DMS delayed match-to-sample; delayed microembolism syndrome; demarcation membrane system; department of ...
DS dead air space; dead space; deep sedative; deep sleep; defined substrate; dehydroepiandrosterone sul...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 12
DIT Diffuse Intimal Thickening
DLBD Diffuse Lewy body disease
DNIC diffuse noxious inhibitory control
DA Diffuse adherence
DAD Diffuse alveolar damage
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • air cell
    ÇԱ⠼¼Æ÷
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
  • Alzheimer's cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • Alzheimers cell
    ¾ËÂêÇÏÀÌ¸Ó ¼¼Æ÷
  • amplifying cell
    Áõ½Ä ¼¼Æ÷
  • anterior horn cell
    Àü°¢ ¼¼Æ÷
  • antibody dependent cell mediated cytotoxicity
    Ç×ü ÀÇÁ¸ ¼¼Æ÷ ¸Å°³ ¼¼Æ÷ µ¶¼º, Ç×ü ÀÇÁ¸¼º ¼¼Æ÷ ¸Å°³¼º ¼¼Æ÷ µ¶¼º
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen binding cell
    Ç׿ø °áÇÕ ¼¼Æ÷
    Ç׿ø¿¡ ´ëÇÑ Æ¯ÀÌÀûÀÎ °áÇձ⸦ ¼¼Æ÷ Ç¥¸é¿¡ °¡Áö°í ÀÖÀ¸¸ç Ç׿øÀ» ¼¼Æ÷ Ç¥¸é¿¡ °áÇÕ½ÃŰ´Â ´É·ÂÀ» °¡Áø ¼¼Æ÷. B ¼¼Æ÷ ¹× ÀϺÎÀÇ T ¼¼Æ÷°¡ Ç׿ø °áÇÕ ¼¼Æ÷¿¡ ÇØ´çµÈ´Ù. À̵éÀÇ ¸²ÇÁ±¸ÀÇ ¼¼Æ÷ Ç¥¸é¿¡ Ç׿øÀÌ °áÇյǾî ÀÖ´Â »óŸ¦ °¢Á¾ ¹æ¹ýÀ¸·Î È®ÀÎÇÒ ¼ö ÀÖ´Ù. Ç׿øÀ» ¹æ»ç¼º ¹°Áú·Î Ç¥ÁöÇØ µÎ°í autoradiogra
  • antitumor k cell
    Ç×Á¾¾ç k ¼¼Æ÷
  • anucleate cell
    ¹«ÇÙ ¼¼Æ÷
    ÇüÅÂÀûÀ¸·Î ºÐÈ­ÇÑ ±¸Á¶·Î¼­ÀÇ ÇÙÀ» °¡ÁöÁö ¾Ê´Â ¼¼Æ÷. ¼¼±ÕÀ̳ª ³²Á¶·ù¿¡¼­´Â ÇüÅÂÀûÀ¸·Î ¶Ñ·ÇÇÏ°Ô ºÐÈ­ÇÑ ÇÙÀÌ ¾ø´Ù. ÀÌ·¯ÇÑ ¼¼Æ÷¸¦ ÇÁ·ÎÄ«¸®¿ÀÆ®
  • APUD cell
    APUD ¼¼Æ÷
    amine
  • arsenical basal cell carcinoma
    ºñ¼Ò¼º ±âÀú¼¼Æ÷ ¾Ï
  • B cell
    B ¼¼Æ÷
    °ñ¼ö¿¡¼­ Çü¼ºµÈ ¸²ÇÁ±¸, ÇüÁú ¼¼Æ÷·Î ÀüȯµÇ¾î Ç×ü¸¦ »ý¼º. ÃéÀåÀÇ ¶û°Ô¸£Çѽº ¼¶¿¡ ÀÖ´Â 4Á¾·ùÀÇ ¼¼Æ÷ Áß Çϳª·Î¼­ Àν¶¸°À» ºÐºñÇÑ´Ù.
  • B cell clone
    B ¼¼Æ÷ Ŭ·Ð
    Ŭ·ÐÀ̶õ ´ÜÀÏÀÇ ¼¼Æ÷¸¦ Á¶»óÀ¸·Î ÇÏ´Â 1±ºÀÇ ¼¼Æ÷¸¦ ¸»ÇÑ´Ù. µû¶ó¼­ B ¼¼Æ÷ Ŭ·ÐÀº ´ÜÀÏÀÇ B ¼¼Æ÷°¡ ºÐ¿­, Áõ½ÄÇÏ¿© Çü¼ºÇÑ B ¼¼Æ÷ Áý´ÜÀ» ¸»ÇÑ´Ù. ÀÌ °æ¿ì µ¿ÀÏÇÑ ¸é¿ª ±Û·ÎºÒ¸° V À¯ÀüÀÚ¸¦ ¹ßÇöÇϰí ÀÖ´Â B ¼¼Æ÷·Î »ý°¢ÇÒ ¼ö ÀÖ´Ù. Á¤»óÀÇ B¼¼Æ÷´Â ¾Æ´ÏÁö¸¸ ¼¼Æ÷À¶ÇÕ¹ýÀ¸·Î ¾ò¾îÁø B ¼¼Æ÷ À¶ÇÕÁ¾µµ ¶Ç B¼¼Æ÷ Ŭ·ÐÀ̶ó°í ºÒ¸®¿ì´Â ¼ö°¡ ÀÖ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
lymphoblastic lymphoma <tumour> A diffuse lymphoma in children, with supradiaphragmatic distribution and T lymphocytes having convoluted nuclei; many patients develop acute lymphoblastic leukaemia.
(05 Mar 2000)
lymphocytic lymphoma <oncology, tumour> A cancer of lymphatic tissues, the tumour cells are mostly abnormal lymphocytes.
(13 Nov 1997)
lymphoma <oncology, tumour> Malignant tumour of lymphoblasts derived from B lymphocytes. most commonly affects children in tropical Africa: both Epstein Barr virus and immunosuppression due to malarial infection are involved.
(18 Nov 1997)
lymphoma, aids-related B-cell lymphoid tumours that occur in association with aids. Patients often present with an advanced stage of disease and highly malignant subtypes including burkitt lymphoma, immunoblastic large-cell lymphoma, small non-cleaved-cell lymphoma and diffuse large-cell lymphoma. The tumours are often disseminated in unusual extranodal sites and chromosomal abnormalities are frequently present. It is likely that polyclonal B-cell lymphoproliferation in aids is a complex result of ebv infection, HIV antigenic stimulation, and T-cell-dependent HIV activation.
(12 Dec 1998)
lymphoma, follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the lymph nodes. The nodules resemble to some extent the germinal centres of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular centre B-lymphocytes. This class of lymphoma usually occurs in older persons, is commonly multinodal, and possibly extranodal. Patients whose lymphomas present a follicular or nodular pattern generally have a more indolent course than those presenting with a diffuse pattern.
(12 Dec 1998)
lymphoma, high-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have a relatively unfavorable survival potential.
(12 Dec 1998)
lymphoma, intermediate-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have an intermediate survival potential.
(12 Dec 1998)
lymphoma, low-grade One of the three major prognostic groupings for non-hodgkin lymphomas as proposed in the working formulation of the non-hodgkin's lymphoma pathologic classification project sponsored by the national cancer institute (1981). Lymphomas falling within this group have a relatively favourable survival potential.
(12 Dec 1998)
lymphoma, lymphoblastic A high-grade malignant lymphoma composed of a diffuse, relatively uniform proliferation of cells with round or convoluted nuclei and scanty cytoplasm. The cells are cytologically similar to the lymphoblasts seen in acute lymphocytic leukaemia, and in some cases, the disease may evolve into a leukaemic phase morphologically indistinguishable from acute t-lymphocytic leukaemia (leukaemia, T-cell, acute). Lymphoblastic lymphoma represents approximately one-third of the cases of non-hodgkin's lymphomas in children and 5% of the cases in adults. It is more prevalent in males.
(12 Dec 1998)
lymphoma, mucosa-associated lymphoid tissue Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire malt tissue as a result of an immunologically mediated disorder.
(12 Dec 1998)
lymphoma, non-hodgkin Any of a group of malignant tumours of lymphoid tissue that differ from hodgkin disease, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumours is the absence of giant reed-sternberg cells, a characteristic of hodgkin's disease.
(12 Dec 1998)
lymphoma, undifferentiated A form of lymphoma in which relatively large stem cells with large nuclei, pale, scanty cytoplasm, and indistinct borders are predominant. The cells are undifferentiated, i.e., show no morphologic evidence of maturation toward lymphocytes or histiocytes.
(12 Dec 1998)
bilaterally small, smooth kidneys <radiology> Generalised atherosclerosis, nephrosclerosis - benign and malignant, atheroembolic renal disease, chronic glomerulonephritis, papillary necrosis, hereditary diseases, hereditary chronic nephritis (Alport's syndrome), medullary cystic disease, amyloidosis (late), arterial hypotension Cf: other urographic patterns
(12 Dec 1998)
generalised small bowel disease <radiology> Hypoproteinaemia, sprue, Whipple
(12 Dec 1998)
mesenteric portion of small intestine The freely movable portion of the small intestine supplied with a mesentery, comprising the jejunum and ileum.
Synonym: mesenteric portion of small intestine.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
  • hammer and sickle
    (ÇØ¸Ó¿Í ³´À¸·Î µÈ)¼Ò·Ã ±¹±â
  • haves and havenots
    ÇÙ º¸À¯±¹°ú ºñº¸À¯±¹;(ÀϹÝÀûÀ¸·Î)°¡Áø ÀÚ(³ª¶ó)¿Í °®Áö ¸øÇÑ ÀÚ(³ª¶ó)
  • hen and chickens
    ±äº´²É(²ÜÇ®°ú);µ¢±¼°í¾Æ´ë¼ö¿°(±¤´ë³ª¹°°ú)
  • hole and corner
    ºñ¹ÐÀÇ;Â÷ÂúÀº
  • hoof and mouth disease
    =FOOT AND MOUTH DISEASE
  • hunt and peck
    ŸÀڱ⸦ Á¦¸Ú´ë·Î Ä¡´Â ÀÏ
  • in and in
    µ¿Á¾ ±³¹èÀÇ(·Î)
  • in and out
    (Áõ±ÇµîÀ» ´Ü±â·Î)¸Å¸ÅÇÏ´Â;(¹Ì¼Ó)µéÂß³¯ÂßÀÇ
  • in and outer
    (¹Ì¼Ó)(ÄÁµð¼ÇÀÌ)°í¸£Áö ¸øÇÑ ¼±¼ö(¿¬¿¹ÀÎ)
  • lares and penates
    Áý¾ÈÀÇ ¼öÈ£½Å;ÅÍÁÖ;°¡º¸;°¡Àç
  • make-and-break
    °³Æó½ÄÀÇ
  • mild and bitter
    ´Ü¸À ¾´¸ÀÀÌ ¹Ý¹ÝÀÎ ¸ÆÁÖ
  • milk and water
    ±èºüÁø;¸ß¾ø´Â;¸÷½Ã °¨»óÀûÀÎ
  • mix and match
    ±ÕÇüÀÌ ¸ÂÁö ¾Ê´Â °Í ³¢¸®ÀÇ Â¦Áö¿ò
  • nuts and bolts
    (±â°èÀÇ)ÀÛµ¿ºÎ(ºÐ);¿îÀü;°æ¿µ;(»ç¹°ÀÇ)±âº» ¿äÁ¡
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 12
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 12
ÅëÇÕ°Ë»ö ¿Ï·á